New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics (Q38289992)

1 September 2017

1 reference

title

New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics (English)

1 reference

1 September 2017

Alison J Smith

1

1 reference

1 September 2017

language of work or name

1 reference

15 December 2014

1 reference

Journal of Biomolecular Screening

1 September 2017

published in

1 reference

1 September 2017

volume

20

1 reference

1 September 2017

issue

4

1 reference

1 September 2017

page(s)

437-453

1 reference

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Human monoclonal antibodies from transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Beyond natural antibodies: the power of in vitro display technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Strategies for selection of antibodies by phage display

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Exploiting recombination in single bacteria to make large phage antibody libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Selecting and screening recombinant antibody libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Fundamentals of antibody-related therapy and diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

The future of antibodies as cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Which are the antibodies to watch in 2013?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Antibodies to watch in 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Biologics: an update and challenge of their pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Neonatal Fc receptor and IgG-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Marketing approval of mogamulizumab: a triumph for glyco-engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Engineered antibody fragments and the rise of single domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Single-domain antibodies as building blocks for novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Nanobodies: natural single-domain antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Nanobodies®: New ammunition to battle viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Engineered antibodies for molecular imaging of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Modulating the pharmacokinetics of therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Development trends for therapeutic antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

"Diabodies": small bivalent and bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

High avidity scFv multimers; diabodies and triabodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Design and application of diabodies, triabodies and tetrabodies for cancer targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Stable IgG-like Bispecific Antibodies Directed toward the Type I Insulin-like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-tumor Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Targeting T cells to tumor cells using bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

A new class of bispecific antibodies to redirect T cells for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Bispecific antibodies for delivery into the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Antitumor immunity: easy as 1, 2, 3 with monoclonal bispecific trifunctional antibodies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Antibody-drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Maturing antibody-drug conjugate pipeline hits 30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Antibody-drug conjugates: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Targeted cancer therapy: conferring specificity to cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Site-specific antibody drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Methods for site-specific drug conjugation to antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

A general approach to site-specific antibody drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Immunocytokines: a novel class of potent armed antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Antibody targeted drugs as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Designing immunoconjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Targeted delivery of a SNARE protease to sensory neurons using a single chain antibody (scFv) against the extracellular domain of P2X(3) inhibits the release of a pain mediator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Small-molecule inhibitors of protein-protein interactions: progressing towards the dream

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Convergent solutions to binding at a protein-protein interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Differential targeting of Gbetagamma-subunit signaling with small molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

The use of cell-penetrating peptides for drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Influence of protein transduction domains on intracellular delivery of macromolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Human-protein-derived peptides for intracellular delivery of biomolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Endosomal escape pathways for delivery of biologicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Stabilizing the pro-apoptotic BimBH3 helix (BimSAHB) does not necessarily enhance affinity or biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Targeting cancer with a lupus autoantibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Intracellular antibody capture: A molecular biology approach to inhibitors of protein-protein interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

In vivo selection of intrabodies specifically targeting protein-protein interactions: a general platform for an "undruggable" class of disease targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Therapeutic antibodies directed at G protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Opportunities for functional selectivity in GPCR antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Emerging opportunities for allosteric modulation of G-protein coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Strategies for the identification of allosteric modulators of G-protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Ligand detection in the allosteric world

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Emerging concepts of guanine nucleotide-binding protein-coupled receptor (GPCR) function and implications for high throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Discrete steps in binding and signaling of interleukin-8 with its receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Functional monoclonal antibody acts as a biased agonist by inducing internalization of metabotropic glutamate receptor 7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Inhibitory Mechanism of an Allosteric Antibody Targeting the Glucagon Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Allosteric inhibition of BACE1 by an exosite-binding antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Atomic Basis for the Species-specific Inhibition of V Integrins by Monoclonal Antibody 17E6 Is Revealed by the Crystal Structure of V 3 Ectodomain-17E6 Fab Complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Monoclonal anti-β1-adrenergic receptor antibodies activate G protein signaling in the absence of β-arrestin recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

TSH Receptor Monoclonal Antibodies with Agonist, Antagonist, and Inverse Agonist Activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

scFv single chain antibody variable fragment as inverse agonist of the beta2-adrenergic receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Modulation of the M2 muscarinic acetylcholine receptor activity with monoclonal anti-M2 receptor antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Identification of key amino acid residues in a thyrotropin receptor monoclonal antibody epitope provides insight into its inverse agonist and antagonist properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Molecular basis for negative regulation of the glucagon receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Functional selectivity through protean and biased agonism: who steers the ship?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Teaching old receptors new tricks: biasing seven-transmembrane receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Conformation state-sensitive antibodies to G-protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Agonistic CD40 antibodies and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Physiological relevance of GPCR oligomerization and its impact on drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

How does voltage open an ion channel?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Coupling of voltage-sensors to the channel pore: a comparative view

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Impact of novel screening technologies on ion channel drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Immunopharmacology: utilizing antibodies as ion channel modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Antibody therapeutics targeting ion channels: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

A novel polyclonal antibody specific for the Na(v)1.5 voltage-gated Na( ) channel 'neonatal' splice form

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Autoantibodies to ion channels at the neuromuscular junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Ca2 channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2 channelopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Voltage‐dependent binding and calcium channel current inhibition by an anti‐α1D subunit antibody in rat dorsal root ganglion neurones and guinea‐pig myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Further advances in the production of membrane proteins in Pichia pastoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Generation of functional ion-channel tools by E3 targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

The antibody targeting the E314 peptide of human Kv1.3 pore region serves as a novel, potent and specific channel blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Mouse monoclonal antibodies to transient receptor potential ankyrin 1 act as antagonists of multiple modes of channel activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Drug delivery to brain via the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Structure and function of the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Blood-brain barrier delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Nanotechnologies: a strategy to overcome blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Functional cell-based assays in microliter volumes for ultra-high throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Novel trends in high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Cell-based assays: fuelling drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

High level production of soluble single chain antibodies in small-scale Escherichia coli cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Antibodies from phage antibody libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Single-chain Fv phage display propensity exhibits strong positive correlation with overall expression levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Feasibility of implementing cell-based pathway reporter assays in early high-throughput screening assay cascades for antibody drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Methodological approaches for the study of GABA(A) receptor pharmacology and functional responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Therapeutic antibody engineering by high efficiency cell screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

A dual-mode surface display system for the maturation and production of monoclonal antibodies in glyco-engineered Pichia pastoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Deep mutational scanning: assessing protein function on a massive scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Deep sequencing of phage display libraries to support antibody discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

The antibody mining toolbox: an open source tool for the rapid analysis of antibody repertoires

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Selecting antagonistic antibodies that control differentiation through inducible expression in embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Selecting agonists from single cells infected with combinatorial antibody libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Converting stem cells to dendritic cells by agonist antibodies from unbiased morphogenic selections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Primary cells and stem cells in drug discovery: emerging tools for high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

The multicellular tumor spheroid model for high-throughput cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

High content screening: seeing is believing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

The beautiful cell: high-content screening in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Increasing the Content of High-Content Screening: An Overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

The Role of Historical Bioactivity Data in the Deconvolution of Phenotypic Screens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell type

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Structure-function of the G protein-coupled receptor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Overview of molecular relationships in the voltage-gated ion channel superfamily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Structure and function of voltage-gated ion channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Recent progress in generating intracellular functional antibody fragments to target and trace cellular components in living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

Monoclonal Antibody Blockade of the Human Eag1 Potassium Channel Function Exerts Antitumor Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1087057114562544

21 January 2018

Identifiers

DOI

10.1177/1087057114562544

1 reference

1 September 2017

1 reference